breast cancer
Conditions
Sponsors
QST Hospital, National Institutes for Quantum and Radiological Sciences and Technology
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Pathologically proven invasive ductal carcinoma or ductal carcinoma in situ. 2. Tumor size <=20 mm on MRI. 3. No massive LVSI or EIC. 4. No lymphenode metastasis (>2 mm). Sentinel lymph node biopsy is performed prior this study. 5. No distant metastasis. 6. Performance status (ECOG) of 0 to 2. 7. 20 years old or older. 8. A life expectancy of at least 6 months. 9. Written informed consent.
Exclusion criteria
Exclusion criteria: 1. Severe complication (e.g. uncontroled lung disease, heart disease, infection, or psychiatric disease). 2. Previous treatment history including surgery, chemotherapy, endocrine therapy, molecular-targeted agents for breast cancer in same side. 3. Active other malignancy 4. The distanse between skin surface and tumor (including EIC) <=5 mm. 5. Previous radiation therapy for breast cancer in same side. 6. Eligible patients for "Breast cancer I". 7. Pregnancy, pregnancy potential. 8. Ptinents who are considered inappropriate by the attending physician due to medical, psychological or other factors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse reaction of normal tissue within 90 days after starting of the treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Adverse reaction of normal tissue in late phase 2. Local effect (CR rate) 3. Local control rate with recommended dose 4. Breast cosmetic outcomes 5. Progression-free survival period 6. Overall survival period | — |
Countries
Japan
Contacts
Public ContactNoriyuki Okonogi
National Institutes for Quantum and Radiological Sciences and Technology QST Hospital
Outcome results
None listed